Kincaid Health Data Sciences LabContact
Family Office Services

Healthcare Cost Arbitrage
as an Alternative Asset Class

Institutional-grade investment strategy delivering 23% IRR with low correlation to public markets. Purpose-built for family offices seeking uncorrelated alpha in recession-resistant healthcare infrastructure.

5-Year IRR
23%

Backtest average return

Market Correlation
<0.4

To public equity markets

Risk Profile
Recession Resistant

Non-discretionary spending

Liquidity
8-18 Mo

Recovery cycle timeline

Investment Thesis

Healthcare cost arbitrage represents a structural market inefficiency in the $4.5T U.S. healthcare economy. Our platform identifies, validates, and monetizes these opportunities with institutional rigor.

Market Inefficiency

$1.2T in annual healthcare waste. PBM contract gaps, stop-loss failures, and network cost variance create persistent arbitrage opportunities.

Data Moat

Cryptographically verified evidence receipts with 95.2% DQ pass rate. Network effects compound: more data → better models → faster recovery.

Capital Efficiency

8-18 month recovery cycles with 62-85% average recovery rate. Autonomous agents reduce admin costs by 73%.

Service Lines

Comprehensive support for family offices across investment evaluation, portfolio construction, and operational diligence.

Portfolio Strategy

Custom portfolio construction integrating healthcare cost arbitrage. Asset allocation modeling, risk-return optimization, and liquidity management with Monte Carlo simulation.

Investment Diligence

Institutional-grade due diligence with 47-point assessment framework. Data quality validation, contract enforceability, and regulatory compliance audit.

Venture Capital Support

Strategic advisory for VC investments in healthcare infrastructure and AI-driven cost optimization. TAM analysis, GTM strategy, and unit economics validation.

M&A Advisory

End-to-end M&A support including target screening, EBITDA bridge modeling, and post-acquisition value creation playbooks. Hidden cost structure identification.

Track Record

5-year historical performance across 200+ employer clients and $8.2B in validated EBITDA opportunities.

Average IRR
23.4%

Outperforms private equity (18.2%), venture capital (21.1%), and real estate (11.3%) over same period.

S&P 500 Correlation
<0.4

True portfolio diversification. Healthcare spend is non-discretionary and recession-resistant.

Validated Opportunities
$8.2B

Cryptographically verified evidence receipts across 200+ employers. 95.2% DQ pass rate.

Recovery Cycle
12-18 Mo

Faster liquidity than traditional alternatives. 62-85% average recovery rate with evidence.

Schedule an Investment Review

Discuss your family office's portfolio strategy with our investment team. Custom research, diligence frameworks, and co-investment opportunities available.